Sat, Dec 27, 2014, 9:53 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

BG Medicine, Inc. (BGMD) Message Board

  • miamigent1 miamigent1 Mar 25, 2014 10:19 PM Flag

    BGMD 9X's 90 DAV today!

    In today @ 2.15 avg
    Vol was tremendous- 9x's 90 DAV
    Chart showing a bullish bottom triangle pattern
    Earnings show steady growth last three qtrs
    MC reasonable @ $58M
    I never underestimate a company from Boston- few fakers up there as opposed to where I live (FL), lol.
    Substantial news today:

    Publication Reports Clinical Utility of BGM Galectin-3(R) Test for Prediction of Near-Term Re-hospitalization in Patients With Heart Failure
    BY Globe Newswire— 8:30 AM ET 03/25/2014

    WALTHAM, Mass., March 25, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) announced today the publication of results, in the American Heart Journal, of an analysis of aggregated data from three large, multicenter clinical research trials in the United States and Europe. The trials included a total of 902 heart failure patients and demonstrated that elevations of galectin-3 levels in blood, as measured using the BGM Galectin-3® Test, were significantly predictive of re-hospitalization for heart failure as early as within the first 30 days following discharge from an initial hospital stay. [1]

    The authors reported that heart failure patients with elevations in their galectin-3 levels at the time of their hospitalization were re-admitted within 30 days at nearly three times the rate of patients without galectin-3 elevation (risk ratio of 2.80 at 30 days, P-value of 0.003). The increased risk conferred by elevations in galectin-3 was seen to persist at 60, 90 and 120 days in the study. Galectin-3 testing correctly identified markedly higher risk among between one-fifth to one-third of all patients who, based on conventional risk assessment, were placed into a low risk category at the time of their initial hospital discharge but who, nonetheless, went on to be re-hospitalized or suffer a fatal event (net reclassification improvement statistic value of +42.6% at 30 days, P-value

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Astounding, what this article shows is that galectin3 testing could save about 25% of the patients who under conventional risk assessment were told they were OK. So now with this test they can eliminate a lot of potential risk assessment errors and save lives. This FDA cleared test will take off very soon in the medical field , and even more so when Abbott Lab gets FDA clearance for the automated version of the test where a few thousand tests can be analysed per hour. This test will probably become routine procedure for cardiac patients and those at risk. Hope to see $3 tomorrow .

      Sentiment: Strong Buy

 
BGMD
0.33+0.0130(+4.10%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.